This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Events, news, and information for the people who influence the business strategies of the life science industry.

reVision Therapeutics on potential fast path for drugs treating rare eye diseases

Share this article

reVision Therapeutics, focused on repurposed drugs for the treatment of ophthalmic diseases, was selected for the Audience Choice award at the BIO-Europe 2018 Startup Slam. President and CEO Paul Fehlner explains his company’s need for seed money to develop their very strong Phase III candidate as well as investment for the early trials of two rare disease candidates to accelerate treatments to those with a variety of eye diseases needing better therapies.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

Upcoming event

Global Partnering

15 Feb - 27 Oct 2021, Delivered Digitally
MEET PARTNERS AND DISCOVER INNOVATION. THREE EVENTS. ONE REDUCED PRICE. HUNDREDS OF OPPORTUNITIES.
Go to site